Trial Profile
An Open-Label, Parallel-Group Study Assessing the Pharmacokinetics, Saftey and Pharmacodynamics of Single Oral Dosing of Luseogliflozin in Patients with Hepatic Impairment (Mild to Moderate) and in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2017
Price :
$35
*
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 21 Sep 2017 New trial record
- 07 Aug 2017 Results published in the Clinical Pharmacology in Drug Development Journal.